2KESSELttE1M A S. The backlash against bioequivalence and the in- terchangeability of brand-name and generic drugs[J]. CMAJ, 2011, 183(12): 1350-1351.
3KOVACIC .1 C, MEHRAN R, SWEENY J, et al. Clustering of acute and subacute stent thrombosis related to the introduction of ge- neric clopidogrel[J]. J Cardiovasc Pharm T, 2014, 19(2): 201-208.
4CARTER B L. Equivalence of generic and brand-name drugs for car- diovascular disease|J].IAMA, 2009, 301~ 16) : 1655-1656.
6MADRID I, VEL~ZQUEZ G, FEFER E. Pharmaceuticals and health sector reform in the americas: an economics perspective[M]. Washington DC: Pan Am6rican Health Organization, 1998.
7FORD, EARL S. Explaining the decrease in US deaths from coro- nary disease, 1980--2000[J1. New Engl J Med, 2007, 356(23) : 2388-2398.
8BERWICK, DONALD M, ANDREW I), et al. Eliminating waste in US health carelJ]. .lAMA, 2012, 307(14): 1513-1516.
